Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

Pfizer

Status: Completed

Conditions: Pneumonia

Treatments: Drug: vancomycin; Drug: linezolid (Zyvox)

Study type: Observational

Funder types: Industry

Identifiers

NCT01819935

A5951163

Details and patient eligibility

About

The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.

Full description

All patients meeting inclusion/exclusion criteria from inpatient database from 1/1/02-9/30/10.

Enrollment: 5,271 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• MRSA and pneumonia cases by ICD-9 code identification.
• Diagnosis included during inpatient stay.
• Treatment initiation in hospital.

Exclusion criteria

• Death of discharge within 3 days of treatment initiation.
• Exposure to other treatments with MRSA activity.

Trial design

5,271 participants in 2 patient groups

linezolid (Zyvox)

Treatment:

Drug: linezolid (Zyvox)

Vancomycin

Treatment:

Drug: vancomycin